Acebilustat - Celtaxsys

Drug Profile

Acebilustat - Celtaxsys

Alternative Names: CTX-4430; EP-501

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Celtaxsys
  • Class Anti-inflammatories; Antiacnes; Antifibrotics; Skin disorder therapies; Small molecules
  • Mechanism of Action Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris; Cystic fibrosis
  • Phase I Bronchiectasis; Hidradenitis suppurativa; Pulmonary hypertension; Skin disorders
  • Preclinical Rosacea

Most Recent Events

  • 10 Feb 2018 Celtaxsys plans phase II trials for Pulmonary hypertension, Bronchiectasis and Bullosa dermatoses in 2018 (Celtaxsys pipeline, February 2018)
  • 09 Feb 2018 Phase-I clinical trials in Bronchiectasis in USA (PO) (Celtaxsys pipeline, February 2018)
  • 09 Feb 2018 Phase-I clinical trials in Pulmonary hypertension in USA (PO) (Celtaxsys pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top